bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean Safety
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
bluebird bio (BLUE) PT Raised to $87 at Maxim Group
December 1, 2016 11:45 AM ESTMaxim Group analyst Jason McCarthy reiterated a Buy rating and lifted his price target on bluebird bio (NASDAQ: BLUE) to $87.00 (from $57.00) following early positive data in Multiple Myeloma.
McCarthy highlighted:
bluebird announced (early) positive data in Multiple Myeloma. The phase 1 study of bb2121 CAR-T, targeting BCMA (B Cell Maturation Antigen) in relapsed/refractory multiple myeloma (r/r MM) treated 11 patients with escalating doses of bb2121. In 9 evaluable patients there was an overall... Morebluebird bio (BLUE) PT Raised to $85 at Leerink Partners
December 1, 2016 11:26 AM ESTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and lowered his price target on bluebird bio (NASDAQ: BLUE) to $85.00 (from $80.00) amid higher confidence in bb2121 for Myeloma.
Schmidt commented, "We are increasing our Price Target (PT) on BLUE shares to $85 from $80... More
bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 Data
December 1, 2016 7:47 AM ESTJefferies analyst Gena Wang reiterated a Buy rating and lifted her price target on bluebird bio (NASDAQ: BLUE) to $88.00 (from $80.00) following 'impressive' initial BCMA CAR-T Ph1 data at ENA.
Wang commented, "BLUE/CELGs anti-BCMA CAR T cells (bb2121) showed promising initial... More
bluebird bio (BLUE) Reports Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate
November 30, 2016 5:28 PM ESTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim data from its ongoing Phase 1 clinical study of bb2121, the companys investigational anti-BCMA CAR T cell product candidate in patients with relapsed/refractory multiple myeloma, will be presented on Thursday, December 1, 2016 at the 28th... More
